3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Melanoma
3
Glioma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Xanthogranuloma, Juvenile
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Laryngeal Neoplasms
1
Histiocytic Sarcoma
1
Hematologic Neoplasms
1
Erdheim-Chester Disease
1
Craniopharyngioma
1
Interventions
trametinib
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Observation
1
Molecular Diagnostic Techniques
1
Indinavir
1
Immunotherapy
1
Fluorodeoxyglucose F18
1
FPP(RGD)2
1
Drug Therapy
1
Docetaxel
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
Vemurafenib
×
CNS
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled